Strength in Motion: Cancer Rehabilitation Program at the Vernon Cancer Center

The following professionally guided exercise classes are free of charge and appropriate for all fitness and energy levels. Come learn how to make exercise and fun and effective!

Exercise Screenings
Screening appointments are available on Wednesday between 8:30 and 10:30 am

Vernon Cancer Center
These informal screenings by a physical therapist provide an overall fitness assessment and recommendations for future exercise plans. The physical therapist can also refer patients for physical or occupational therapy for specific concerns.

Rehabilitation Exercise Class
When: Friday, 11:00 am – noon
Where: Department of Rehabilitation Services Small class size, rolling admission for 10-week sessions. This exercise class, led by a physical therapist, offers gentle aerobic exercise, strength training and stretching.

Shipley Fitness Center
When: Tuesday, 11:00 am – noon
Where: Shipley Fitness Center
Small class size, rolling admission for 10-week sessions. This class, led by an exercise physiologist at the Shipley Fitness Center, offers a more vigorous aerobic exercise, strength training and stretching. Personal training is also available.

Clinical Trials June 2011

New England Hematology/Oncology Associates, along with Newton-Wellesley Hospital’s Clinical Research Team, offers patients access to a variety of clinical trials of promising new therapies. Review the list below to find open protocols and consider referring your patients. The Cancer and Leukemia Group B (CALGB) is a national clinical research group.

As a clinical trials affiliate and CALGB affiliate of Dana-Farber/Partners CancerCare, Newton-Wellesley Hospital participates directly in DF/PCC-led clinical research. This allows our patients to have access to many of the same studies being conducted at Boston’s premier cancer research hospitals.

The network has made it possible for hundreds of cancer patients to enroll in clinical trials. People who had difficulty participating in trials because they lived far from Boston now have access to some of the latest investigational therapies at a hospital near them. Last year, the affiliates enrolled 160 patients in DF/PCC-sponsored trials and CALGB trials combined.

To learn more about eligibility and participation contact a member of the clinical research team.
Newton-Wellesley Hospital Office of Research Manager: Hope Violette, RPh, CIP | Phone: 617-243-6493 | Email
Newton-Wellesley Hospital Oncology Research Nurse: Kara Malcolm, RN | Phone: 617-243-5089 | Email
Newton-Wellesley Hospital Oncology Research Coordinator: Judy Chow | Phone: 617-243-6392 | Email
Medical Director of Oncology Research: Caroline Block, MD | Phone: 617-658-6000| Email

Breast Cancer

CALGB 40502 (Breast – Metastatic 1st Line)
Randomized phase III trial of weekly paclitaxel compared to weekly nanoparticle albumin bound nab-paclitaxel Phase III or ixabepilone, all combined with bevacizumab, as first -line therapy for locally recurrent or metastatic breast cancer. DF# 08-360. More Info…

CALGB 40601 (Breast – HER2-positive Neoadjuvant)
Randomized Phase III Trial Of Paclitaxel Combined With Trastuzumab, Lapatinib, Or Both As Neoadjuvant Treatment Phase III Of Her2-Positive Primary Breast Cancer. DF# 08-370 More Info…

370CALGB 40603 (Breast – Triple Negative Neoadjuvant)
Randomized Phase II 2 X 2 Factorial Trial Of The Addition Of Carboplatin +/- Bevacizumab To Neoadjuvant Weekly Phase II Paclitaxel Followed By Dose dense AC In Hormone Receptor-Poor/Her2-Negative Resectable Breast Cancer. DF# 09-260. More Info…

DF 94-138 (Breast, Ovarian – Banking/Registry) Genetics and Other Causes of Cancer
The REACH project collects risk factor information, blood and tissue specimens from patients and family members at high risk for breast and/or ovarian cancer. The data and specimen bank will be used as a resource to be shared with researchers working in the areas of breast and ovarian cancer risk, prevention and treatment. DF# 94-138

GI Cancer

CALGB 80405 (Colon – Metastatic)
A Phase III Trial of Irinotecan / 5-FU / Leucovorin or Oxaliplatin / 5-FU / Leucovorin with Bevacizumab, or Cetuximab Phase III (C225) for Patients with Untreated Metastatic Adenocarcinoma of the Colon or Rectum. DF# 05-449 More Info…

Lung Cancer

CALGB 30704 (NSCLC – 2nd Line treatment)
A Randomized Phase II Study To Assess The Efficacy Of Pemetrexed Or Sunitinib Or Pemetrexed Plus Sunitinib In Phase II The Second-Line Treatment Of Advanced Non-Small Cell Lung Cancer. DF# 08-144 More Info…

Lymphoma

CALGB 50501 (Lymphoma – Treatment)
A Phase II Trial Of Bortezomib and Lenalidomide For Relapsed or Refractory Mantle Cell Lymphoma DF# 08-066 More Info…

Click below to see more information about the active clinical trials:

Oncology Research Summer Newsletter 2010

Oncology Research Winter Newsletter 2010

Oncology Research Spring 2011